<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1543350091153">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">27.11.2018 20:21:31 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.1pzu0e4ehnyfz</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>What company are you calling from? &lt;a href=&quot;http://www.bombeirodf.com.br/stmap_50f80.html?zyban.tadaga.glycomet.cialis&quot;&gt;zofran injection pediatric dose&lt;/a&gt;  A new study has found that the vast majority of rheumatoid arthritis (RA) patients in the US being treated with Amgen&amp;rsquo;s Enbrel (etanercept) and AbbVie&amp;rsquo;s Humira (adalimumab) are biologic-na√Øve and, therefore, taking these drugs as their first-line biologic treatment.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
